Name: KPHMW Balance Sheet - Kiora Pharmaceuticals Assets & Debt | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Total Assets, Current Assets, Cash and Equivalents, Total Liabilities, Long-term Debt, Short-term Debt, Shareholders Equity, Working Capital, Book Value Per Share

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

KPHMW - Kiora Pharmaceuticals Inc.

USD | NASDAQ | Healthcare

KPHMW Balance Sheet - Kiora Pharmaceuticals Assets & Debt | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Cash And Short Term Investments
Cash And Equivalents	8.7	3.8	2.5	6.0	7.9	1.2	3.8	8.0	7.8	3.6	8.4	0.2	0.5
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Term Investments	8.4	23.0	0.0	-	-	-	-	-	-	-	-	-	-
Cash And Short Term Investments	17.1	26.8	2.5	6.0	7.9	1.2	3.8	8.0	7.8	3.6	8.4	0.2	0.5
Receivables
Accounts Receivable	1.5	0.6	0.0	-	-	-	-	-	-	-	-	-	-
Current Assets
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Expenses	1.1
Non-Current Assets
Property, Plant & Equipment Gross	0.1	0.0	0.0	0.2	0.2	0.1	0.1	0.1	0.1	0.0	0.3	0.3	-
Accumulated Depreciation
Current Liabilities
Accounts Payable	1.1	0.4	0.2	1.0	0.2	0.4	0.2	0.1	0.7	1.4	0.4	0.6	-
Short Term Debt	-
Non-Current Liabilities
Long Term Debt	-	-	-	-	-	0.3	0.0	-	-	-	-	-	-
Operating Lease Liabilities Non-Current	0.2
Common Equity
Common Stock	0.3	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.1	0.0	-
Additional Paid In Capital	170.3
Supplementary Data
Total Debt	-	-	-	-	-	0.3	0.0	-	-	-	-	-	-
Net debt	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Cash And Short Term Investments
Cash And Equivalents	11.0	8.7	5.5	1.0	3.8	3.8	5.6	6.6	31.3	2.5	5.4	8.0	3.4	6.0	4.8

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Common Equity
Common Stock	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.4	0.4	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
Additional Paid In Capital	170.5	170.3	170.1	169.8	169.3	169.2	169.0	168.8	168.4	153.2	153.0	152.7	146.7	146.0	142.7	135.7	135.6
Retained Earnings	(156.6)	(154.2)	(147.7)	(147.7)	(145.6)	(143.4)	(139.2)	(135.7)	(133.5)	(147.0)	(144.7)	(138.9)	(136.3)	(134.5)	(132.0)	(126.8)	(124.4)
Accumulated Other Comprehensive Income	(0.2)	(0.2)	(0.2)	(0.2)	(0.3)	(0.3)	(0.1)	(0.2)	(0.3)	(0.2)	(0.3)	(0.2)	(0.2)	(0.2)	(0.3)
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders Equity	13.9	16.1	22.4	22.1	23.7	25.8	30.0	33.1	34.9	6.1	8.1	13.6	10.2	11.4	10.5	8.8	11.3
Total Equity	13.9	16.1	22.4	22.1	23.7	25.8	30.0	33.1	34.9	6.1	8.1	13.6	10.2	11.4	10.5	8.8	11.3	14.6

Supplementary Data
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.3	0.3	0.3	0.3	-	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Working Capital	15.9	18.1	20.1	21.6	21.8	23.7	28.1	30.2	31.9	3.1	4.9	7.1	3.5	4.4	3.6	1.5	4.0	7.4
Book Value	13.9	16.1	22.4	22.1	23.7	25.8	30.0	33.1	34.9	6.1	8.1	13.6	10.2	11.4	10.5	8.8	11.3	14.6
Tangible Book Value	11.9	14.1	15.7	15.4	17.0	19.1	23.3	24.3	26.1	(2.7)	(0.7)	2.9	(0.6)	0.7	(0.2)	(2.0)	0.5